Tags : CD30 CAR-T

$Tessa’s CD30 CAR-T Therapy Receives EMA’s PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma$

Tessa’s CD30 CAR-T Therapy Receives EMA’s PRIME Designation for Relapsed

Tuba Khan January 19, 2021

Shots: The PRIME designation is based on two Phase I/II studies in R/R cHL conducted at Baylor College of Medicine and the University of North Carolina Lineberger Comprehensive Cancer Center […]readmore

Tags : CD30 CAR-T

Tessa’s CD30 CAR-T Therapy Receives EMA’s PRIME Designation for Relapsed

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : CD30 CAR-T

Tessa’s CD30 CAR-T Therapy Receives EMA’s PRIME Designation for Relapsed

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company